Core Insights - Silence Therapeutics plc reported financial results for Q4 and the full year ended December 31, 2025, highlighting a focus on clinical execution and progress in their pipeline [1] Financial Performance - The company provided an update on its financial results, indicating a strong emphasis on clinical trials and operational advancements [1] Clinical Development - The Phase 2 SANRECO trial of divesiran in PV is progressing well, with expedited enrollment and expected topline results in the third quarter [1]

Core Viewpoint - Silence Therapeutics plc announced the departure of Craig Tooman as President and CEO effective December 14, 2025, with Iain Ross taking over as interim leader [1][2]. Company Leadership Changes - Craig Tooman's exit was by mutual consent, and he has been with the company since 2022 [1]. - Iain Ross, the Chairman of the Board, will lead the company on an interim basis [2]. - James Ede Golightly has been re-appointed to the Board, and an additional US-based Board member is expected to be appointed soon [2]. Company Overview - Silence Therapeutics is a clinical-stage biotechnology company focused on developing siRNA therapies to target and silence disease-associated genes, particularly in the liver [3]. - The company aims to address high unmet medical needs in areas such as cardiovascular disease, hematology, and rare diseases [3].